Skip to content

Video Assisted Study of Salbutamol Response in Viral Wheezing

Video Assisted Study of Salbutamol Response in Viral Wheezing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06093152
Acronym
ViVi
Enrollment
50
Registered
2023-10-23
Start date
2023-10-23
Completion date
2026-12-31
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wheezing

Brief summary

The study is video assisted cross-over study evaluating the effect of inhaled salbutamol in wheeze in children 6-24 months old.

Detailed description

The object of the study is to evaluate the effect of inhaled salbutamol in wheeze in children 6-24 months old. In despite of the lack of evidence of salbutamol, it is considered the gold standard in acute wheezing. Placebo-controlled study would be unethical so all participants are treated with salbutamol based on current guidelines. Instead, participants serve as control subjects of their own which is executed by a type video assisted cross-over study. Participants are filmed before and after the treatment. Afterwards a panel of pediatricians not participating in the treatment of the participants independently evaluates the difficulty of the wheeze. Videos are randomly arranged and members of the panel are blinded to the time point (before/after) of videos. In addition, collected videos are analyzed using machine vision. Biosignals are collected from the videos and evaluated using algorithms in order to show that machine vision can be utilized to evaluate the difficulty of wheezing. The machine vision analysis is compared to the evaluation of the panel of pediatricians.

Interventions

DRUGSalbutamol

Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.

Sponsors

University of Oulu
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to 24 Months
Healthy volunteers
No

Inclusion criteria

* Wheezing * Salbutamol-treatment in emergency department prescribed

Exclusion criteria

* Need for immediate resuscitation * Immediate transfer to ICU * Suspicion of pneumonia based on the auscultation finding * Suspicion of airway foreign body

Design outcomes

Primary

MeasureTime frameDescription
Change in modified RDAIWithin 3 hours of study entryRDAI = Respiratory Distress Assessment Instrument, modified to not include auscultation findings. Range 0-18. Higher score indicates more difficult respiratory distress. Evaluated by the blinded panel afterwards using collected videos. Videos collected immediately before and after the intervention.

Secondary

MeasureTime frameDescription
Change in saturation of peripheral oxygenWithin 3 hours of study entryChange in saturation measured immediately before and after the intervention.
Change in auscultation findingWithin 3 hours of study entryEvaluated by review of medical records (i.e. based on the findings of the physician treating the patient). Assessed as difficult (wheezing lasting all expiration and possibly inspiration in all 4 lung fields), medium (no inspiratory wheezing, lasting all expiratory OR in all lung 4 fields) of mild (no inspiratory wheezing, wheezing not lasting all expiratory and not in all lung fields). Assessed immediately before and after the intervention.
Change in the difficulty of the respiratory distressWithin 3 hours of study entrySubjective evaluation of the respiratory distress based on the appearance of the patient on the video. Range 0-10, higher score indicating more difficult respiratory distress. Assessed by the blinded panel afterwards using videos collected immediately before and after the intervention.
Machine-vision assisted analysis of respiratory statusWithin 3 hours of study entryMachine vision analysis of the difficulty of wheezing (none - mild - difficult). Assessed using videos collected immediately before and after the intervention.

Countries

Finland

Contacts

Primary ContactVille Lindholm, MD
Ville.a.lindholm@oulu.fi+35883155283

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026